Astellas Seals Deal For Ocata
This article was originally published in Scrip
Executive Summary
After a few months hanging in limbo because of disgruntled investors, Astellas Pharma Inc. has finally completed its $379m deal for the US clinical-stage regenerative cell therapy venture, Ocata Therapeutics Inc., winning over more than 50% of outstanding shares at its original offer of $8.50 per share.